Recent News

Carmell Therapeutics Advances Plasma-based Products with $4M Series B Support

US-based regenerative medicine company Carmell Therapeutics is developing a patented technology that enables the delivery of growth factors directly to injured sites in order to promote the healing of bone and soft tissue, as well as reduce infections. The company’s plasma-based bioactive material (PBM) technology derives from Carnegie Mellon University in Pittsburgh, Pennsylvania, from which Carmell spun out in 2007. The technology has time-release capabilities to accelerate healing, with the active biologics released over different time periods as the PBM biodegrades at the injured site.

Read More >

Carmell® Therapeutics is presenting at the Biotech and Money World Congress in London on 5-6th of February, 2018

Carmell® Therapeutics is presenting at the Biotech and Money World Congress in London on 5-6th of February 2018.  If you would like to meet with Randy Hubbell, CEO, please email at

Carmell Therapeutics Named Pittsburgh Tech 50 Awards Finalist

Pittsburgh Technology Council Names Category Leaders on October 12, 2017

PITTSBURGH, PA – Carmell Therapeutics, a privately-owned biotechnology company focused on the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs), today announced that the Pittsburgh Technology Council has named it a Tech 50 Category Leader in the Innovator of the Year: Life Sciences Category.

Read More >

Stephanie Kladakis, Ph.D., Vice President, Research & Development, Carmell Therapeutics: Harvard School of Engineering and Applied Sciences Alumni Spotlight

Harvard John A. Paulson School of Engineering and Applied Sciences website.

A physician can make a positive impact on every patient, but an engineer who develops the right biomedical device could potentially help millions of people suffering from an illness or injury.

Alumna Stephanie Kladakis, S.B. ’96, is that engineer.

Read More >


Carmell™ Therapeutics closes $4M Series B round of funding

Carmell™ Therapeutics announced the issuance of Canadian Patent No. 2701187 for METHODS AND APPARATUS FOR MANUFACTURING PLASMA BASED PLASTICS

Carmell™ Therapeutics expands manufacturing capabilities to support Phase III clinical trials

Carmell Therapeutics New Management Team

Carmell announces the awarding of a new U.S. Patent that covers the use of the Company’s plasma-based materials as drug delivery vehicles

Dr. James Hart joins Carmell Therapeutics as new Chief Medical Officer

Randy Hubbell appointed as President and Chief Executive Officer

Carmell Therapeutics’ Plasma-Based Materials Shown to be Effective Antibiotic Delivery Vehicles

Research Notebook: Carmell Therapeutics’ PBMs—A new paradigm for healing tissue and bone

Carmell Therapeutics Ends 2014 with Addition of a New Patent to its Growing Portfolio

Pittsburgh researchers' bone putty could revolutionize how broken bones mend

Paper Describing Carmell Therapeutics’ Clinical Data Receives Coveted GT du Toit Award from the South African Orthopaedic Association

First Clinical Use of Carmell Therapeutics’ Plasma-Based Biomaterial Reduces Infections, Speeds Healing of Bone Fractures

Natural Infection Reduction: first reported use of a novel blood plasma-based product for treating open tibia fractures

Carmell Therapeutics Receives NIH Phase I Grant to develop antimicrobial-eluting bioresorbable bone filler.

Carmell Innovation Showcase Winner at ACA 2014 Summit

September 10, 2013: Five new U.S. Patents issued

Can New Plasma-Based Biomaterials Speed Healing of Injured Tissues?